


Valens™ T4AH

Novel TLR4 Agonist & Aluminum Hydroxide Adjuvant System




Valens™T4AH: similar system to MPLA + Alum

Valens T4AH is an adjuvant system combining **INI-2002**, a fully synthetic TLR4 agonist, adsorbed onto **aluminum hydroxide gel**. The composition is comparable to adjuvant systems already approved for human vaccines, including those for HPV and Hepatitis B.

In vivo murine vaccination study:


When paired with a weakly immunogenic SARS-CoV-2 antigen, Valens T4AH elicited strong Th1 responses. While INI-2002 or alum alone were sufficient to generate antibody responses, only the combination triggered a robust cellular immune response.



Key Advantages:

- Adjuvant patent protection through 2039
- Scalable manufacturing process suitable for commercial production; engineering lot completed
- Excellent thermal stability

Stability of T4AH at 40°C



RUO samples, relevant Data and expert Assistance are Available to Support your Development.

www.spipharma.com

salesinfo@spipharma.com

All information and statements given in this bulletin are believed to be accurate at the time of publication. However, neither SPI Pharma nor any of their affiliates make any representations or warranty with respect thereto, including, but not limit to, any results obtained in the processing of the products by customers or any third party. All information and statements are intended for persons having the required skill and know-how and do not relieve the customer or user from verifying the suitability of information and statements given for a specific purpose prior to use of products. It is entirely the obligation of the costumer or user to comply with applicable laws and regulations, and with all patent or other intellectual property rights of third parties.